Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Public ClinicalTrials.gov record NCT01678963. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy of topical ophthalmic squalamine lactate eye drops in treating patients with neovascular age-related macular degeneration (wet AMD), a degenerative retinal eye disease that causes a progressive, irreversible, severe loss of central vision.
Study identification
- NCT ID
- NCT01678963
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 142 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2012
- Primary completion
- Feb 28, 2015
- Completion
- Feb 28, 2015
- Last update posted
- Jun 11, 2015
2012 – 2015
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Retina Associates SW | Tucson | Arizona | 85710 | — |
| California Retinal Consultants | Bakersfield | California | 93309 | — |
| Retina-Vitreous Associates | Beverly Hilss | California | 90211 | — |
| Colorado Retina | Golden | Colorado | 80401 | — |
| Florida Eye Microsurgical Institute Inc. | Boynton Beach | Florida | 33426 | — |
| Retina Health Center | Fort Myers | Florida | 33907 | — |
| Midwest Eye Institute | Indianapolis | Indiana | 46290 | — |
| Elman Retina | Baltimore | Maryland | 21237 | — |
| Cumberland Valley Retina Consultants | Hagerstown | Maryland | 21740 | — |
| Ophthalmic Consultants of Boston | Boston | Massachusetts | 02114 | — |
| Vision Research Foundation | Grand Rapids | Michigan | 49546 | — |
| Vision Research Foundation | Royal Oak | Michigan | 48073 | — |
| Vision Research Foundation | Traverse City | Michigan | 49686 | — |
| Total Practice Management | New Brunswick | New Jersey | 08901 | — |
| Macula Care | New York | New York | 10021 | — |
| Retina Associates of Cleveland | Cleveland | Ohio | 44122 | — |
| PA Retina | Camp Hill | Pennsylvania | 17011 | — |
| TN Retina | Nashville | Tennessee | 37203 | — |
| Medical Center Ophthalmology Associates | San Antonio | Texas | 78240 | — |
| University of Wisconsin | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Neovascular Age Related Macular Degeneration trials
Other public records listing Neovascular Age Related Macular Degeneration. Sorted by last update posted; newest first. Not a recommendation.
- NCT07614776: A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration Recruiting
- NCT06660667: A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration Active, not recruiting
- NCT05904028: Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD Recruiting
- NCT04853251: A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) Recruiting
- NCT04704921: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD Active, not recruiting
- NCT03683251: Extension Study for the Port Delivery System With Ranibizumab (Portal) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01678963, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2015 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01678963 live on ClinicalTrials.gov.